Compare Ford Motor Company (F) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Travere Therapeutics Inc. Common Stock — how do they compare? Ford Motor Company trades at $12.03 (market cap $48.25B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Ford Motor Company is far larger — about 9.9× Travere Therapeutics Inc. Common Stock's market cap, and Ford Motor Company pays a 4.96% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| F | TVTX | |
|---|---|---|
Market Cap | $48.25B | $4.88B |
Volume | 33,627,673 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $67.52 |
52-Week Low | $11.21 | $26.79 |
Typical Hold Time | 105 Days | 0 Days |
Enterprise Value | $180.21B | $5.01B |
Dividend Yield | 4.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.05, up 0.42% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI conditions. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and declining sales trends. Recent news highlights supplier disruptions affecting F-150 production and a 6.6% Q3 sales decline, though the company maintains its No. 3 U.S. market position.
Ford faces significant challenges with negative profitability and competitive pressures, though analyst consensus suggests 31% upside to the $15.79 price target. The stock presents a value opportunity given low P/S and P/B ratios, but investors must weigh operational headwinds against the company's strong commercial division and ongoing hybrid vehicle transition.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
